David G. Glazer advises and represents life sciences, healthcare, and technology companies in matters throughout the United States, Europe, and Asia. Working closely with clients to understand their businesses, David structures and negotiates deals to meet their objectives and find practical solutions to complex problems. David’s clients range from biotechnology startups to global Fortune 100 pharmaceutical companies.
David negotiates and structures licensing and other complex collaborations, corporate partnering arrangements, strategic alliances, mergers and acquisitions (M&A), spin-outs, supply and distribution arrangements, co-promotions, and joint ventures. He works on early-stage research collaborations, global alliances, and developing and commercializing products. David brings a background in drug and medical device development and commercialization, early-stage research and development of late-stage product deals, and issues related to the life sciences industry such as indication, field, and territory splitting.
David also counsels medical device, including digital health and specialty pharmaceutical companies, as well as private equity, venture capital (representing investors and entrepreneurs), and investment banking firms that focus on the life sciences industry.
He authors and co-authors articles about the life sciences industry, as well as guest lectures to law students and MBA candidates about licensing in the life sciences industry.
Represented PTC Therapeutics, Inc. in its acquisition of Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of a clinical-stage investigational therapy for orphan metabolic diseases
CRISPR Therapeutics in its license agreement with KSQ Therapeutics using CRISPR technology to enable the CRISPR Therapeutics’ drug discovery engine to achieve higher probabilities of success in drug development. Under the license agreement, CRISPR Therapeutics will gain access to KSQ intellectual property for editing certain novel gene targets in its allogeneic oncology cell therapy programs, and KSQ will gain access to CRISPR Therapeutics’ intellectual property for editing novel gene targets identified by KSQ as part of its current and future engineered tumor infiltrating lymphocyte cell programs.
Advanz Pharma in its acquisition of rights to two established medicines, Salagen® and Panretin® from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments
Eli Lilly in its up-to-$560 million partnership with Atomwise to develop up to ten drug targets selected by Lilly, using Atomwise’s artificial intelligence technology
Merck in its up to $5.76 billion strategic collaboration with Eisai Co. Ltd. for the worldwide co-development and co-commercialization of Eisai's Lenvima (lenvatinib mesylate)
SQZ Biotechnologies in its $1.37B-plus deal with Roche for a new approach to immuno-oncology where Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development milestones and another $250 million for each new therapy that manages to receive approval and Roche and SQZ will jointly develop anticancer cell therapies that trigger antitumor responses with cell therapies that can target antigens that are beyond the reach of other cell-based adoptive immunity strategies
Aurobindo in its acquisition from Novartis selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio for $900 million of cash plus $100 million of potential earn-outs
Eli Lilly in its agreement with NextCure, Inc. for the discovery and development of immuno-oncology therapies to discover novel cancer targets utilizing NextCure's proprietary FIND-IO™ platform. Under the terms of the agreement, Lilly and NextCure will each receive options to exclusively license antibodies resulting from the collaboration.
Nevakar Inc. in its $50 million product financing agreement with an affiliate of NovaQuest Capital Management, for the continued development of five differentiated, sterile injectable products
Regeneron in its up to $1 billion agreement with Alnylam Pharmaceuticals for the development and commercialization of new RNA interference therapeutics for diseases in the eye, central nervous system and liver. As part of the transaction, Regeneron made a $400 million investment in Alnylam equity.
Merck in its up to $8.5 billion strategic oncology collaboration with AstraZeneca to co-develop and co-commercialize AstraZeneca's Lynparza (olaparib) and AstraZeneca's selwnetinib
Nevakar Inc. in its exclusive licensing agreement with Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the U.S. and Canada
Regeneron in its agreement with bluebird bio to develop and commercialize new cell therapies for cancer. As part of the transaction, Regeneron made a $100 million investment in bluebird bio common stock.
Merck in its strategic collaboration and license agreement with Moderna to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck’s established leadership in immuno-oncology with Moderna’s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers.
AbbVie in its global collaboration and license agreement with Halozyme to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE™ platform. Under the terms of the agreement, Halozyme will receive an initial $23 million payment, followed by milestone payments totaling approximately $130 million for each of up to nine collaboration targets and tiered royalties if products under the collaboration are commercialized.
Merck in its license and collaboration agreement with Moderna for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA)
Ironwood in its licensing agreement with AstraZeneca for the exclusive US rights to Zurampic® pursuant to which Ironwood acquired exclusive US rights to Zurampic and the exclusive US rights to the fixed-dose combination of lesinurad and allopurinol. Ironwood will pay AstraZeneca sales-related and other milestone payments of up to $265 million and tiered single-digit royalties on Product Sales
Merck in its $14.2 billion agreement to sell its consumer care business to Bayer
Merck in its collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase modulators, under which Bayer receives a $1 billion up-front payment with the potential for additional milestone payments
Celgene in its drug-discovery collaboration with Cancer Research Technology (CRT), to discover, develop and commercialize new anti-cancer treatments centered on mRNA translation
Merck in its joint venture with Sun Pharmaceutical Industries, a leading Indian multinational pharmaceutical company, to develop, manufacture and commercialize new combinations and formulations of innovative, branded generics in the emerging markets
BTG in the sale of its brachytherapy business to Eckert & Ziegler
Lumiphore in its agreement with Algeta for worldwide license to Lumiphore’s patented chelator technology to be used for cancer therapeutics
Lundbeck in its commercial rights agreement with Cephalon to register and commercialize several Cephalon products including Fentora, Provigil, Treanada, Trisenox, Myocet, and Nuvigil in Canada and Latin America
BTG in the $180 million acquisition of EKOS Corporation
MEI Pharma in its acquisition from S*BIO of the rights to Pracinostat, a clinical stage oncology drug
Eli Lilly in its multi-year, multibillion dollar clinical and research agreements with Covance Inc.
LifeNet Health in its acquisition of Northwest Tissue Services from Puget Sound Blood Center
Represented international specialty pharma company in its multimillion dollar transformative manufacturing arrangement, whereby it transitioned the manufacture of several specialty pharmaceutical products to a contract manufacturer
NPS Pharmaceuticals in the restructuring and sale of its mGluRs collaboration with AstraZeneca
Represented a biotechnology company in negotiation of complete supply chain agreements, including with two API manufacturers, two bulk drug manufacturers, two packaging providers, and the supply agreement with its collaboration partner for the finished product in both the United States and Europe
Novo Nordisk in its agreement with Sciele Pharma for Sciele to market Prandin® and, upon approval by the US Food and Drug Administration, PrandiMet
Assisted a European/US company to negotiate clinical trial agreements with more than 25 sites in the U.S. in neuropharm product area.
A biotechnology company in its master services agreement and clinical trial agreements with an international clinical research organization
Schering-Plough in its global collaboration with Novartis to develop and commercialize a once-daily inhaled fixed-dose combination therapy for asthma and COPD
New York University School of Law, 1997, J.D.
Rutgers University, 1994, B.A.
Awards and Affiliations
Ranked, Corporate/M&A, New Jersey, Chambers USA (2008–2009, 2013–2020)
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Life Sciences Star, Finance and Corporate, LMG Life Sciences (2012–2019)
Member, New Jersey Bar Association
Articles Editor, New York University Environmental Law Journal